BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous ...

U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...

The settlement payment of $467 million related to a contractual dispute with the University of Pennsylvania is expected to be reflected in the Company's second quarter 2025 financial results. In ...

March 10 (Reuters) - German COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion ...

BioNTech's Q4 2024 revenue surpassed estimates, totaling 1.19 billion euros. EPS reached 1.08 euros, vastly exceeding the expected 0.42 euros, showcasing strong earnings management. Revenue from ...

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for malaria prevention. The hold includes BioNTech’s investigational ...

In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a clinical hold on BioNTech’s Investigational New Drug ...

Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel. BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties BioNTech has entered into two separate ...